Christian Hurtz, PHD

Loma Linda University – Assistant Professor and Director, Leukemic Therapy Development Program

Dr. Christian Hurtz is an Assistant Professor at Loma Linda University School of Medicine and Director of the Leukemic Therapy Development Program. His research focuses on uncovering mechanisms of drug resistance in high-risk B-cell acute lymphoblastic leukemia (B-ALL) and translating these insights into targeted therapies. Dr. Hurtz has made significant contributions to the understanding of BCL6 and pre-BCR signaling in leukemia, as well as the identification of DYRK1A as a context-specific therapeutic vulnerability in KMT2A-rearranged ALL. His laboratory integrates CRISPR screening, functional genomics and in vivo modeling using murine and patient-derived xenograft systems.
Prior to his faculty appointment, Dr. Hurtz completed postdoctoral training at the University of Pennsylvania and the University of California San Francisco, and he received his PhD from the University of Freiburg in Germany.